Award will fund development of Qana’s metabolically-targeted therapeutic for adrenocortical carcinoma.
AUSTIN, TEXAS, April 3, 2024 – Qana Therapeutics, an Austin-based biotechnology company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute. The funding will support Qana’s program to treat adrenocortical carcinoma (ACC), a rare tumor of the adrenal gland, with a novel, metabolically-targeted approach. Metastatic ACC has a generally poor prognosis with a five-year survival rate of roughly 15%.
“We are grateful for the support from the team at the National Cancer Institute to advance our targeted anti-cancer strategy in this cancer of high unmet need,” said Jim Graham, CEO.
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N10024C00008.